LearnGlossaryMarketStocksSuperinvestorsSign in

SRZN

Surrozen, Inc.

Healthcare · $221M market cap

Verdict

We can't put a fair value on SRZN right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-42.7% a year✗
Sales growth-34.7% a year✗
Free cash flow growth—?
Return on invested capital-53.4%✗

Follow SRZN

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Oct 20, 2026: no open-market purchases and 72 other filings (stock awards, tax withholding and similar). Why purchases matter

Other filings

Svennilson Peter

Owns 10%+ · 2026-10-20

X-InTheMoney

$3.0M

Svennilson Peter

Owns 10%+ · 2026-10-20

X-InTheMoney

$3.2M

Svennilson Peter

Owns 10%+ · 2026-10-20

X-InTheMoney

$2.8M

Svennilson Peter

Owns 10%+ · 2026-10-20

X-InTheMoney

$9.0M

Svennilson Peter

Owns 10%+ · 2026-10-20

X-InTheMoney

$9.5M

Questions about SRZN

Are insiders buying SRZN?

Since Oct 20, 2026: no open-market purchases and 72 other filings (stock awards, tax withholding and similar).

How can I check SRZN's value myself?

Use the free Sticker Price calculator, already filled with SRZN's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →

Similar stocks · Biotechnology

MDXGMiMedx Group, Inc.3.93On Sale
INVAInnoviva, Inc.21.06Overpriced
GENSFGenus plc28.14Overpriced
HRMYHarmony Biosciences Holdings, Inc.36.03Fairly Valued
LGNDLigand Pharmaceuticals Incorporated307.82Overpriced

About Surrozen, Inc.

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Oct 23, 2026. How the Payback Price works